



HAL
open science

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Harbouring MET Exon 14 Skipping Mutation and PD-L1 $\geq 50\%$ (GFPC 01-20 Study)

Florian Guisier, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, Remi Veillon, Alexis B Cortot, Claire Tissot, Christos Chouaid, Chantal Decroisette

► To cite this version:

Florian Guisier, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, et al.. Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Harbouring MET Exon 14 Skipping Mutation and PD-L1 $\geq 50\%$ (GFPC 01-20 Study). *Clinical Lung Cancer*, 2022, 23 (8), pp.e545-e549. 10.1016/j.clcc.2022.09.002 . hal-04141332

HAL Id: hal-04141332

<https://hal.u-pec.fr/hal-04141332>

Submitted on 26 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring *MET* Exon 14 Skipping Mutation and PD-L1 $\geq 50\%$ (GFPC 01-20 Study)

Florian Guisier,¹ Renaud Descourt,² Helene Babey,² Eric Huchot,³ Lionel Falchero,⁴ Remi Veillon,⁵ Alexis B. Cortot,⁶ Claire Tissot,⁷ Christos Chouaid,⁸ Chantal Decroisette⁹

Clinical Practice Points

- Pembrolizumab is a valid option for first-line treatment of stage IV NSCLC with PD-L1 $\geq 50\%$ and *MET* exon 14 skipping mutation.
- Best outcomes were seen in adenocarcinomas (vs. squamous cell carcinoma or sarcomatoid carcinoma)

Clinical Lung Cancer, Vol. 23, No. 8, e545–e549 © 2022 The Author(s). Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Keywords: Immunotherapy, *MET* exon 14 skipping mutation, non-small cell lung cancer, oncogenic addiction, biomarker

Introduction

Genomic studies of large cohorts have unraveled a complex molecular landscape of lung tumors. Targeted therapies for several oncogenic alterations have been developed and improve patients' outcomes. In stage IV non-squamous non-small cell lung cancer (NSCLC) patients, *MET* exon 14 skipping mutations (*MET* Δ 14) were described in 2003 and is found in 1% to 4% NSCLC. The resulting protein escapes ubiquitination and degradation and confers cell survival, proliferative and invasive properties to the cell.¹ Several *MET* inhibitors have been evaluated for the treatment of *MET* Δ 14 NSCLC.²⁻⁴

Since 2015, anti-Programmed Death 1 (PD1) and anti-Programmed Death Ligand 1 (PD-L1) immunotherapy has emerged as a gold-standard treatment for second-line treatment and more recently for first-line treatment for of stage IV NSCLC, either in monotherapy or in combination with chemotherapy. In these studies, no information was reported regarding the *MET* Δ 14 NSCLC subgroup. Efficacy of anti-PD1/PD-L1 in these patients is largely unknown. Pathophysiologically, *MET* alterations may induce PD-L1 expression,² hence *MET* Δ 14 may affect response to anti-PD1/PD-L1 immunotherapy. In 147 *MET* Δ 14 NSCLC patients, Sabari et al. found a higher PDL1 expression than expected, with 22%, and 41% having PD-L1 expression of 1% to 49%, and $\geq 50\%$, respectively.⁵ Nevertheless, median TMB of *MET* Δ 14 NSCLC was lower than that of unselected NSCLCs. Similar results were recently reported in 2 series of 14 and 20 *MET* Δ 14 NSCLC.^{6,7}

Several observational studies reported the results of anti-PD1/PD-L1 immunotherapy in molecularly defined subgroups including *MET* Δ 14 NSCLC, mainly in second and more lines, with mixed results. In the above-mentioned study by Sabari et al. 24 patients (11 as first-line treatment) were treated with anti-PD1/PD-L1 immunotherapy. Among 22 patients evaluable for response, objective response rate (ORR) was 17% and median progression free survival (PFS) and overall survival (OS) were 1.9 months and 18.2 months (95% CI 12.9-NR), respectively.⁵ The Immunotarget study reported results from 36 patients treated with anti-PD1/PD-L1 in second line and more: ORR was 16%, PFS 3.4 months.⁷ In a similar study, we reported 30 more patients treated in first line

¹Department of Pneumology and Inserm CIC-CRB 1404, Normandie Univ, UNIROUEN, LITIS Lab QuantIF team EA4108, CHU Rouen, Rouen, France

²Institut de cancérologie, Hopital Morvan, CHRU Brest, Brest, France

³CHU sud Reunion, Service de Pneumologie, Saint-Pierre, France

⁴L'Hôpital Nord-Ouest, Service de Pneumologie et Cancérologie Thoracique, Villefranche Sur Saône, France

⁵CHU Bordeaux, service des maladies respiratoire, Bordeaux, France

⁶CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, Univ. Lille, Plasticity and Resistance to Therapies, Lille, France

⁷Department of Medical Oncology, Institut de Cancérologie Lucien-Neuwirth, Saint-Etienne, France

⁸Department of Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France

⁹Department of Pneumology, CH Annecy-Genevois, Annecy, France

Submitted: Jun 25, 2022; Revised: Sep 4, 2022; Accepted: Sep 5, 2022; Epub: 17 September 2022

Address for correspondence: Florian Guisier, MD, PhD, CHU Rouen, Service de Pneumologie, 1 rue de Germont, F-76000, Rouen, France
E-mail contact: florian.guisier@chu-rouen.fr

1525-7304/\$ - see front matter © 2022 The Author(s). Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

<https://doi.org/10.1016/j.clc.2022.09.002>

(n = 4), second line (n = 15) or more (n = 11), with ORR 36% and PFS 4.9 months.⁸ Recently, a series of 6 METΔ14 NSCLC patients with long-term benefit of anti-PD1 therapy in ≥ 2nd line was also reported.⁹

To further evaluate the efficacy of anti-PD1 immunotherapy in METΔ14 NSCLC in the first-line setting, we gathered data from 3 academic cohorts conducted by the French lung cancer group (GFPC) that included a subgroup of patients who received pembrolizumab as first-line treatment for metastatic METΔ14 NSCLC with PDL1 ≥ 50%.

Materials and Methods

Study Design

We collected data from 3 independent retrospective, multicenter cohorts conducted: IMAD2 (GFPC 01-2018),⁸ AFONMET (GFPC 03-2018)¹⁰ and ESCKEYP (GFPC 05-2018).¹¹

From these 3 cohorts, patients who met the following criteria were included in the present study: age > 18 years, metastatic NSCLC with METΔ14 mutation, PDL1 ≥ 50%, first-line treatment with pembrolizumab. Patients included in a clinical immunotherapy trial were excluded.

Data Collection

Patients' demographic and clinical characteristics at NSCLC diagnosis were obtained from patient files and included: age; sex; smoking status; cancer stage; number and sites of metastases; presence of METΔ14 mutation; the Eastern Cooperative Oncology Group performance status (ECOG PS) at immunotherapy onset; clinical response to pembrolizumab; adverse event (AE) type and grade on pembrolizumab; and post-immunotherapy treatment.

Statistical Analyses

PFS was defined as the time from pembrolizumab initiation to first subsequent tumor progression. Progression was defined as Response Evaluation Criteria In Solid Tumors version 1.1 criteria (RECIST 1.1) radiological or clinical progression (deteriorated clinical status preventing systemic treatment) or death. Assessments were done in each participating center without centralized imaging review. OS was calculated from pembrolizumab introduction to death. ORR to pembrolizumab was defined as the best response according to RECIST1.1 (radiological assessment was done every 6 weeks). AEs were reported according to Common Terminology Criteria for Adverse Events (CTCAEs) version 4.

The Kaplan–Meier method was used to estimate PFS and OS.

All statistical analyses were computed with the RStudio statistical software (Version 1.1.383).

Ethical Considerations

The study was conducted in accordance with the Declaration of Helsinki. Participating centers were responsible for obtaining patient consent and institutional approval. All contributors were trained in good clinical practices. The study was purely an academic collaboration and was not funded by industry.

Table 1 Patients Characteristics

	Patients (n = 24)
Age (median, range, yr)	73.0 (53-89)
Male	13 (56%)
Smoking status	
Never smoker	8 (33%)
Former smoker	11 (46%)
Active smoker	5 (21%)
Performance status	
0-1	21 (88%)
> 1	3 (12%)
Histology	
Adenocarcinoma	17 (71%)
Squamous cell carcinoma	3 (13%)
Sarcomatoid carcinoma	2 (8%)
Others	2 (8%)
Metastatic sites	
Number (median, range)	3 (1-5)
Lymph nodes	11 (46%)
Bone	9 (38%)
Lung	9 (38%)
Pleura	7 (29%)
Adrenal glands	5 (21%)
Brain	4 (17%)
Liver	3 (13%)

Results

Patients Characteristics

Twenty-four advanced METΔ14 NSCLC patients were included in the study.

Patients characteristics are summarized in Table 1. Median age was 73, 54% were male, 33% were never-smoker, 71% had adenocarcinoma. Median number of metastatic sites was 3 (range: 1-5). Four (17%) patients had brain metastasis, of whom 2 received SBRT before immunotherapy onset. Co-mutations in *BRAF*, *KRAS* and *P53* were identified in 1 patient each.

ICI Therapy and Clinical Outcomes


Median follow up was 12.0 months (IC96 [10.5-NR]). Median duration of first line Pembrolizumab therapy was 3.4 months (IC96 [1.9-8.9]) (Figure 1).

Among 21 of 24 (87.5%) evaluable patients, ORR was 43% (complete response: 14%, partial response: 29%) and disease control rate was 57%. Nine patients (43%) had progressive disease at first tumor assessment. All tumor responses were seen in adenocarcinomas. Median DoR was 13.9 months (95%CI = [8.3-NR]).

Treatment was stopped in 21 of 24 (87.5%) patients: 13 (54%) for tumor progression, 5 (21%) for toxicity and 2 (8%) for having reach 2 years of treatment. Three patients were still on treatment at data cut-off. Nine (38%) patients received a MET inhibitor as subsequent therapy.

Median PFS and OS in the overall cohort were 3.5 months (95%CI = [2.0 – NR]) and 12.1 months (95%CI = [9.1-

Figure 1 Swim-lane plot showing patients treatments and outcomes.



NR]), respectively (Figure 2); in the adenocarcinoma subgroup PFS and OS were 5.3 months (95%CI = [2.1-NR]) and 17.9 months (95%CI = [10.5-NR]), respectively. One-year PFS and OS were 35.8% (95%CI = [20.3-63.1]) and 55.0% (95%CI = [37.6-80.5]), respectively, in the overall population and 46.7%(95%CI = [27.2-80.2]) and 63.8%(95%CI = [42.8-95.2]), respectively, in the adenocarcinoma subgroup. Two-year OS was 30.8% (95%CI = [15.2-62.6]) in the overall population and 44.7% (95%CI = [23.3-85.5]) in the adenocarcinoma subgroup.

Safety

Grade 2 toxicity was reported in 2 (8%) patients (cutaneous and pneumonitis, 1 each), and 3 (12%) patients developed a grade 3 toxicity (cutaneous, renal insufficiency and pneumonitis, 1 each). No grade 4 or 5 toxicity was observed.

Discussion


In this real-world series of 24 stage IV *METΔ14* NSCLC patients with PLD1 > 50%, first-line treatment with pembrolizumab resulted in a median OS of 12.1 months in the entire cohort and 17.9 months in the subgroup of 17 patients with adenocarcinoma. PFS were 3.5 (95%CI = [2.0-NR]) and 5.3 months (95%CI = [2.1-NR]), respectively. These results are worse than those reported from the KEYNOTE 024 and 042 studies, where median OS in patients with PDL1 TPS ≥ 50% receiving first-line Pembrolizumab were 30.0 (C95, [18.3-NR]) and 20.0 months

(95%CI = [15.4-24.9]), respectively.^{12,13} Nevertheless, real-world studies reporting the efficacy of first-line Pembrolizumab in stage IV NSCLC showed contrasted results. In a French retrospective multi-center longitudinal study of 108 consecutive NSCLC patients with PD-L1 TPS ≥ 50% and without EGFR/ALK alterations treated with first-line pembrolizumab, median PFS was 10.1 months (95% CI, 8.8-11.4), ORR was 57.3% and 6-months OS was 86.2%.¹⁴ In a US medico-administrative study of 423 NSCLC patients with PDL1 TPS ≥ 50% who received first-line pembrolizumab, median PFS and OS were respectively 6.8 months (95%CI = [5.3-8.1]) and 18.9 months (95%CI = [14.9-25.5]) and ORR was 48%.¹⁵ These results are in line with ours, especially for adenocarcinomas.

The efficacy of anti-PD1/PD-L1 treatment in *METΔ14* NSCLC patients has also to be discussed in the context of emerging targeted therapies. First generation anti-MET inhibitors were not specifically designed for this purpose but rather targeted ALK, RET or ROS-1. Their clinical activity in *MET* exon 14 skipping mutated NSCLC was usually weak.² Nevertheless, an updated analysis of the PROFILE-1001 study, in which 69 *METΔ14* NSCLC patients were treated with crizotinib, showed 3 complete responses and 18 partial responses (ORR, 32% [95%CI = [21-45]) with median PFS of 7.3 months (95%CI = [5.4-9.1]).

Results of Capmatinib, a new-generation MET inhibitor, were reported in 28 *METΔ14* NSCLC patients treated in the first-line setting (median age 71 years, 55% females, PS 0 23%, adeno-

Figure 2 Kaplan-Meier estimates for progression-free (A, C) and overall survival (B, D) in the overall population (A, B) and among adenocarcinoma patients (C, D).



carcinoma 77%, never smoker 89%, brain metastasis 11%). ORR was 68% (95% CI, 48-84) in 20 evaluable patients, PFS was 12.6 months (95%CI=[5.6-NR]) and median DoR was 12.4 months (95%CI = [8.2-NR]).⁴ In a phase II trial evaluating Tepotinib, another new-generation MET inhibitor, 43 *MET*Δ14 NSCLC patients were treated in the first-line setting. Efficacy results were reported for the overall 152 NSCLC patients included in the trial³; showing an ORR of 46% (95%CI = [36%-57%]) and a median DoR of 11.1 months (95%CI = [7.2 -NR]).³ The phase 1 CHRYSALIS study also included a cohort of patients with *MET*Δ14 NSCLC, that were treated with Amivantamab, a bispecific MET and EGFR antibody. Patients received 2 (range, 0-10) prior lines of therapy in median. In 36 evaluable patients, overall response rate was 33% (50% [3/6] in treatment-naïve patients, 46% [5/11] in patients with no prior MET inhibitor, and 21% [4/19] in patients with prior MET inhibitor therapy).¹⁶ Nevertheless PD-L1 status was not reported in these 3 studies, as well as ICI treatment.

Our study has limitations, notably its retrospective nature and the absence of independent review committee. ORR might be over-estimated by investigators, whereas AEs might be under-estimated

because of the retrospective nature of the study. The size of the cohort is also limited but *MET*Δ14 NSCLC is a rare subtype and we included only patients with PDL1 TPS ≥ 50%.

In conclusion, first-line treatment with Pembrolizumab in PDL1 ≥ 50% NSCLC with *MET* exon 14 skipping mutation may represent a treatment option, especially in adenocarcinoma. This treatment regimen should be assessed prospectively together with chemo-immunotherapy and targeted therapies.

Disclosure

The study was purely an academic collaboration and was not funded by industry.

References

1. Van Der Steen N, Giovannetti E, Pauwels P, et al. cMET Exon 14 skipping: from the structure to the clinic. *J Thorac Oncol.* 2016;11:1423–1432.
2. Bylicki O, Paleiron N, Assié JB, Chouaid C. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date. *Oncol Targets Ther.* 2020;13:5691–5706.
3. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with. *N Engl J Med.* 2020;383:931–943.
4. Wolf J, Seto T, Han JY, et al. Capmatinib in *MET* Exon 14-mutated or *MET*-amplified non-small-cell lung cancer. *N Engl J Med.* 2020;383:944–957.

5. Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. *Ann Oncol.* 2018;29:2085–2091.
6. Dudnik E, Bshara E, Grubstein A, et al. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). *Lung Cancer.* 2018;124:117–124.
7. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol.* 2019;30(8):1321–1328.
8. Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of Anti-PD-1 immunotherapy in patients with advanced NSCLC With BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. *J Thorac Oncol.* 2020;15:628–636.
9. Mayenga M, Assié JB, Monnet I, et al. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. *Lung Cancer.* 2020;150:21–25.
10. Descourt R, Le Gac G. GFPC 03-2018_AFONMET 14 2018 Available from: <http://www.g-f-p-c.org/etude-afonmet-14-r-descourt-g-le-gac/>. Access date: 3/oct/2022
11. Descourt R. GFPC 05-2018_ESCKEYP 2018 Available from: <http://www.g-f-p-c.org/etude-esckey-p-r-descourt/>. Access date: 3/oct/2022
12. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab vs. chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. *Lancet.* 2019;393:1819–1830.
13. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab vs. platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. *J Clin Oncol.* 2019;37:537–546.
14. Amrane K, Geier M, Corre R, et al. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 \geq 50% in a multicenter real-life cohort: The PEMBREIZH study. *Cancer Med.* 2020;9:2309–2316.
15. Velcheti V, Chandwani S, Chen X, Piperdi B, Burke T. Pembrolizumab for previously treated, PD-L1-expressing advanced NSCLC: real-world time on treatment and overall survival. *Clin Lung Cancer.* 2020;21:e445–ee55.
16. Krebs M, Spira A, Cho B, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. *J Clin Oncol.* 2022;40:9008 (suppl 16; abstr 9008).